KOSDAQReal Estate & REITs142760

MOA Life Plus

₩117 0.00%2026-11-18 close
Market Cap
₩2.5B
Turnover
₩0
Volume
0 shares
Shares out.
21.8M
PER
—
PBR
0.1×
EPS
-₩591
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales recovery and listing review overlap at MOA Life Plus

MOA Life Plus has posted operating losses since 2022 and revenue has fallen for three straight years, and net profit attributable to controlling shareholders turned positive in the third quarter of 2026, but trading was halted on November 12, 2026 after a change in the largest shareholder triggered a KOSDAQ listing-eligibility review.

  1. 1

    On a DART-filed basis, revenue fell from KRW 100.4 billion in 2022 to KRW 11.2 billion in 2025, declining for three straight years from 2023.

  2. 2

    The company recorded an operating loss in each year from 2022 to 2025, and the 2025 operating loss widened to KRW 6.53 billion.

  3. 3

    Net profit attributable to controlling shareholders turned positive at KRW 494 million in the third quarter of 2026, while the operating loss of KRW 1.28 billion kept the operating line in deficit for five consecutive quarters.

  4. 4

    On November 12, 2026, a forced sale of collateralized shares changed the largest shareholder, and a listing-eligibility review trigger led to a trading halt the same day.

  5. 5

    The company is pushing PGA-based health supplements and cosmetics through Japanese online channels and raw material supply deals.

02

Business structure

MOA Life Plus builds its business around poly-gamma-glutamic acid (PGA), a naturally derived ingredient that the company says is extracted from fermented foods such as cheonggukjang, and uses it in health supplements, cosmetics and beauty devices.

A 2026 press report said the company is growing both finished cosmetics made from its own raw materials and raw material supply to global cosmetics companies. Distribution is broadening across several channels.

Domestically it signed a supply deal with Yewon Global H, operator of the functional cosmetics brand Beauty Romance, to secure offline shelf space, and it opened an influencer-led sales mall.

Abroad it signed a supply contract with DHOLIC COMMERCE, a Japanese K-beauty e-commerce platform, and listed on Rakuten, Qoo10 and Yahoo Japan Shopping, and it says it is also pursuing entry into Europe.

At its annual shareholder meeting on March 31, 2026, the company amended its articles to add AI data center construction and operation, AI platform development and services, and electronic payment and fintech services to its business purposes.

The new businesses are still at the articles-of-incorporation stage, and their revenue contribution is not separately visible in the DART-filed results. The company attributed the earlier revenue decline to the end of the COVID-19 period and intensifying market competition. Revenue breakdown by segment is not available in the filed results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩1.5B−124.4%
2025Q4₩4.6B-₩2.8B−60.7%
2026Q1₩2.3B-₩1.4B−58.2%
2026Q2₩2.3B-₩1.2B−52.8%
2026Q3₩1.1B-₩1.3B−112.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩100.4B-₩14.6B-₩23.1B−14.6%−106.7%120.5%
2023₩18.2B-₩5.2B₩8.1B−28.3%24.5%37.1%
2024₩15.6B-₩5.5B-₩7B−35.4%−18.7%53.7%
2025₩11.2B-₩6.5B-₩13.1B−58.2%−42.7%39.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a DART-filed basis, revenue fell from KRW 100.4 billion in 2022 to KRW 18.2 billion in 2023, a decline of 81.8%, and then to KRW 15.6 billion in 2024 (down 14.3%) and KRW 11.2 billion in 2025 (down 28.2%), extending a three-year decline. Among the years from 2022 to 2025, 2022 was the largest and 2025 the smallest.

The operating loss was KRW 14.6 billion in 2022, narrowed to KRW 5.16 billion in 2023, widened to KRW 5.54 billion in 2024 and to KRW 6.53 billion in 2025. The operating margin moved from -14.6% in 2022 to -28.3% in 2023, -35.4% in 2024 and -58.2% in 2025, as revenue shrank faster than losses could be reduced.

Net loss attributable to controlling shareholders was KRW 23.1 billion in 2022, turned to a net profit of KRW 8.07 billion in 2023, returned to a net loss of KRW 6.97 billion in 2024 and widened to KRW 13.1 billion in 2025.

Total net income including non-controlling interests was a loss of KRW 33.7 billion in 2022, so the two measures diverge in that year. The company cited lower revenue, higher cost of sales and larger valuation losses on derivatives as the main reasons for the 2025 net loss.

In October 2025 the company said it recovered US$6.7 million, about KRW 9.6 billion, from its Israeli joint venture Quntrigen, producing a gain of KRW 2.4 billion over book value, but how that gain was reflected in the 2025 results cannot be separated from the filed figures.

Quarterly revenue rose from KRW 1.18 billion in the third quarter of 2025 to KRW 4.61 billion in the fourth quarter, a rise of 290.3%, then fell to KRW 2.33 billion in the first quarter of 2026, down 49.5%, held at KRW 2.34 billion in the second quarter and was KRW 1.15 billion in the third quarter of 2026, down 3.0% from a year earlier.

The operating loss was KRW 1.36 billion, KRW 1.23 billion and KRW 1.28 billion in the first three quarters of 2026, and the third-quarter 2026 net profit attributable to controlling shareholders of KRW 494 million followed a net loss of KRW 7.91 billion in the prior quarter.

The aggregate net loss attributable to controlling shareholders over the last four quarters was KRW 12.5 billion.

05

Industry analysis

The company falls under the Real Estate and REIT sector classification, but its actual business is closer to health supplements, cosmetics and PGA raw material supply.

REIT-listed peers in the same classification, such as Macquarie Korea Infrastructure Fund, SK REIT and Lotte REIT, are compared on rental income and dividend structures, so they are not a direct comparison framework. The practical comparison set is health supplement and functional cosmetics companies.

In cosmetics, interest in skin health has pushed cosmeceuticals, which combine cosmetics and pharmaceuticals, into focus. The company is building its functional cosmetics around its own PGA ingredient. On the raw material side, a 2026 report said PGA is being supplied to global cosmetics companies.

Overseas, growth in Japanese K-beauty online channels is cited as an opportunity, and the company says it is expanding supply to Japanese offline stores and pursuing trademark filings in Japan.

Domestically, market competition was cited as a factor behind the earlier earnings decline: cumulative revenue for the first nine months of 2025 fell 46.9% year on year, with lower medical device and supply sales and weak health supplement sales given as reasons.

The company also highlights progress in its drug pipeline, but how those efforts appear in the revenue mix of the filed results is not yet visible.

06

Outlook

A 2026 press report said the company is treating 2026 as the first year of an earnings turnaround and expanding its cosmetics and raw material businesses.

Independent research firm Aris said in a January 29, 2026 report that after restructuring its portfolio, the company would enter a phase of rising earnings from 2026. The company says it will stabilize its PGA-based health supplements, cosmetics and beauty devices while running AI data center projects alongside.

Because AI-related items were added to the business purposes in a March 2026 articles amendment, the concrete revenue plan and investment scale of the new businesses are the next items to watch.

On the funding side, a third-party allotment announced on September 29, 2026 raises KRW 4.0 billion for operating funds, with planned use of KRW 2.0 billion in 2026 and KRW 2.0 billion in 2027, at a face-value issue price of KRW 1,000.

The company said the largest shareholder would change to Medtech Investment Partnership once payment for those shares is completed, and on November 12, 2026 a disclosure reported that shares pledged by the former largest shareholder, MOA Data, were sold in a forced sale.

The outcome of the listing-eligibility review is the nearest decision point for the going-concern assumption and the timing of trading resumption.

The next periodic report, the 2026 annual report, is due by the end of March 2027 under statutory deadlines, and it will show full-year 2026 revenue, fourth-quarter operating results and the revenue contribution from Japan and the planned European entry.

07

Valuation

PER
—
PBR
0.1×
ROE
-47.4%
EPS
-₩591
BPS
₩1,073
Dividend per share
₩0

Multiples move daily with the share price. Because the aggregate net loss attributable to controlling shareholders over the last four quarters remains negative, the price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits well below 1x, and market capitalization is far smaller than the book equity on the balance sheet. Persistent operating losses and listing-process risk are cited as possible reasons the share price stays low relative to asset value. Dividend payouts are effectively absent at present.

On a multi-year view, net profit attributable to controlling shareholders turned positive in 2023 but returned to losses in 2024 and 2025, and the third quarter of 2026 turned positive again while operating losses continued.

Per-share figures and past valuation bands change as filings are updated, so the current level is best read against the latest filings shown alongside the market data.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Turn to profit in the third quarter of 2026

Net profit attributable to controlling shareholders was KRW 494 million in the third quarter of 2026, reversing a net loss of KRW 7.91 billion in the prior quarter. It is the first profit on that measure in the last five quarters on a DART-filed basis.

The operating loss of KRW 1.28 billion in the same quarter was smaller than a year earlier. Because this is a single quarter, the trend in upcoming periodic reports will determine whether it marks a recovery.

Japan channels and raw material supply expanding

The company signed a supply contract with DHOLIC COMMERCE, a Japanese K-beauty e-commerce platform, and listed its products on Rakuten, Qoo10 and Yahoo Japan Shopping. A 2026 press report says PGA is being supplied to global cosmetics companies. The company says it is also pursuing entry into Europe.

Japan revenue is not separately broken out in the filed results, so it becomes a checkpoint in the 2026 annual report.

Lower debt burden on the balance sheet

The debt-to-equity ratio was 39.4% at the end of 2025, down from 120.5% in 2022, with total liabilities of KRW 12 billion and total equity of KRW 30.6 billion. Operating cash flow was positive KRW 6.18 billion in 2023. Lower debt relative to equity reduces near-term financing pressure compared with earlier years. However, operating cash flow returned to an outflow of KRW 5.97 billion in 2025.

09

Bear factors

Three straight years of revenue decline

Revenue fell to KRW 18.2 billion in 2023, KRW 15.6 billion in 2024 and KRW 11.2 billion in 2025, a third straight annual decline, and 2025 was the smallest year in the 2022 to 2025 span.

Quarterly revenue was KRW 2.33 billion in the first quarter of 2026 and KRW 2.34 billion in the second, and KRW 1.15 billion in the third, down 3.0% from a year earlier. The KRW 4.61 billion spike in the fourth quarter of 2025 did not carry into the following quarters. If revenue recovery does not show up in results, fixed cost burden could widen losses.

Persistent losses and cash outflow

The operating line has been in deficit for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the aggregate net loss attributable to controlling shareholders over the last four quarters is KRW 12.5 billion.

Operating cash flow was negative in both 2024 at KRW 502 million and 2025 at KRW 5.97 billion. The company cited lower revenue, higher cost of sales and derivative valuation losses as reasons for the 2025 net loss.

Listing eligibility and governance uncertainty

Since October 20, 2026, the shortfall in market capitalization has been added as a ground for designation as a managed issue, alongside the share price shortfall. On November 12, 2026 a change in the largest shareholder was disclosed and a listing-eligibility review was triggered, halting trading.

A disclosure the same day listed zero shares held by the former largest shareholder after the pledge was released. Business continuity and the funding plan are open questions during this governance transition.

10

Risk factors

Listing eligibility and trading halt

A listing-eligibility review was triggered, and trading has been halted since 16:27 on November 12, 2026 until the decision date. Depending on the outcome, the company either remains listed or enters delisting procedures. Delisting procedures tied to market capitalization have been deferred under a court injunction. Removal from managed-issue status requires meeting the thresholds for a set period of trading days.

Funding needs and share dilution

A September 2026 third-party allotment was set to raise KRW 4.0 billion, with new shares issued at a face value of KRW 1,000. A separate allotment of two million shares for KRW 2.0 billion was also disclosed around the same time.

If operating funds continue to come from equity issuance, share count growth and dilution remain an issue. The planned use of KRW 2.0 billion in each of 2026 and 2027 also points to a tight funding position.

Governance change and execution of new businesses

The largest shareholder changed through a forced sale of pledged shares, and the company said Medtech Investment Partnership would become the largest shareholder once payment for its new shares is completed.

The March 2026 articles amendment added AI data center, platform and fintech purposes, but their revenue contribution and investment scale are not yet visible in filings. If the new businesses do not offset weakness in the existing health supplement and cosmetics revenue, the loss structure could persist. Management direction after the ownership change is also an item to monitor.

11

What to watch next

  1. After November 19, 2026, at the KRX decision disclosure

    The listing-eligibility review outcome and whether trading resumes. The decision determines whether the going-concern basis for listing holds.

  2. After November 19, 2026, when managed-issue removal criteria are met

    Whether the market capitalization and share price thresholds are met for the required number of trading days. A shortfall extends managed-issue status.

  3. End of March 2027 (statutory deadline for the 2026 annual report)

    Full-year 2026 revenue and operating results, fourth-quarter figures, and the revenue contribution from Japan and the planned European entry. This is the baseline for checking continuity with the last five quarters.

  4. During 2027 (planned use of the allotment proceeds)

    The actual spending of the KRW 2.0 billion planned for 2027 and the business direction after the ownership change. It shows both reliance on external funding and any change in strategy.

12

Overall view

MOA Life Plus saw revenue fall from KRW 100.4 billion in 2022 to KRW 11.2 billion in 2025, with operating losses recorded in each of the four years.

Net profit attributable to controlling shareholders turned positive at KRW 494 million in the third quarter of 2026, but the operating loss of KRW 1.28 billion extended a five-quarter run of losses. Quarterly revenue has stayed at a low level since the fourth-quarter spike in 2025.

The debt-to-equity ratio fell to 39.4% at the end of 2025 from 120.5% in 2022, but operating cash flow was an outflow of KRW 5.97 billion in 2025. The change in the largest shareholder, the listing-eligibility review and the trading halt on November 12, 2026 have added several items to the going-concern check.

The key items for the next periodic report are whether the new businesses and Japanese channels show up in the revenue mix of the filed results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. view.asiae.co.kr
  3. startuptoday.co.kr
  4. m.news.nate.com
  5. biz.heraldcorp.com
  6. sentv.co.kr
  7. scoreport.kr
  8. butler.works
  9. ibtomato.com
  10. asiae.co.kr
  11. specialtimes.co.kr
  12. specialtimes.co.kr
  13. specialtimes.co.kr
  14. specialtimes.co.kr
  15. specialtimes.co.kr
  16. kormedi.com
  17. news.nate.com
  18. topstarnews.net

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis